周四盘前，器官移植技术公司TransMedics Group Inc.（股票代码：TMDX）股价大涨13.28%，投资者对公司发布的强劲第二季度财报反应积极。该公司业绩远超华尔街分析师预期，并上调了全年收入指引。
根据公司发布的财报，TransMedics第二季度调整后每股收益达到0.92美元，是分析师平均预期0.45美元的两倍多。公司营收同比增长37.7%，达到1.5737亿美元，同样超过了分析师预期的1.4786亿美元。这一亮眼业绩凸显了公司OCS和NOP平台在移植市场上的强劲竞争力。公司还保持了61%的高毛利率，净利润达到3490万美元，占营收的22%，显示出良好的盈利能力和运营效率。
除了强劲的季度业绩外，TransMedics还上调了2025财年的全年营收指引至5.85亿美元至6.05亿美元，较此前预测有显著提升。公司总裁兼首席执行官Waleed Hassanein博士表示，这一表现反映了公司战略的成功执行及其在移植市场的独特领导地位。此外，TransMedics还宣布获得FDA有条件的研究设备豁免批准，可以启动Next-Gen OCS™肺部试验，进一步增强了投资者对公司未来发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.